Navigation Links
Final 12 Month Clinical Data from 5,000 Patients in Worldwide e-HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM)

SAN FRANCISCO, Sept. 22 /PRNewswire/ -- OrbusNeich today announced that the final 12-month clinical data from the global e-HEALING clinical study showed that the company's Genous Bio-engineered R stent is safe and effective in real world use, including in the treatment of patients with diabetes mellitus.

The study evaluated 4,987 of the 4,996 enrolled patients and found a target vessel failure (TVF) rate of 8.1 percent at 12 months with a follow-up rate of 92 percent, a target lesion revascularization (TLR) rate of 4.4 percent, a major adverse cardiac events (MACE) rate of 7.7 percent, a subacute thrombosis (SAT) rate of 0.5 percent and a late stent thrombosis (LST) of 0.3 percent. The combined SAT and late thrombosis rate of 0.8 percent was per protocol. Per Academic Research Consortium (ARC) definition, the definite and probable SAT and late thrombosis rate is 1.0 percent. The data were presented by Professor Robbert de Winter, M.D., Ph.D., of the Academic Medical Center in Amsterdam at the Transcatheter Cardiovascular Therapeutics symposium, TCT 2009, in San Francisco.

"The excellent study design, electronic data capture and monitoring as well as comprehensive data management resulted in robust data for the e-HEALING clinical study, which further supports the efficacy and safety of the Genous Bio-engineered R stent," said de Winter, a co-principal investigator of the study. "We are especially pleased to see positive results in certain subsets of patients, such as diabetic patients, which often present as challenging cases with an expected higher incidence of in-stent-restenosis."

Twenty five percent of the patients in the study had diabetes mellitus. In a poster presentation, also at TCT 2009, de Winter and colleagues reported data from an analysis of this subset of the e-HEALING study. The 12-month follow-up from these 1,243 patients with diabetes mellitus showed a low TLR rate of 4.6 percent, a per protocol SAT and late thrombosis rate of 0.9 percent, and a MACE rate of 8.9 percent.

"The MACE rate is only 1.2 percent higher than the full cohort of the study and was mainly driven by mortality," said de Winter. "We expect a higher mortality rate in diabetic patients due to other comorbidities."

e-HEALING is a multi-center, worldwide (outside the United States) prospective clinical study conducted in 31 countries at 144 clinical centers. In addition to 25 percent of patients having diabetes mellitus, 42.4 percent of the patients had unstable angina and 11 percent had pre-procedure thrombus. For the lesions treated, 49.3 percent were type B2 or C. The study protocol recommends that patients receive one month of clopidogrel treatment after the index procedure. The primary endpoint of the study is target vessel failure at 12 months. The advanced electronic data capture via the internet with built in consistency checks for data monitoring was conducted by KIKA Clinical Solutions, a leading provider of advanced EDC solutions for clinical trials. Cardialysis, an independent Contract Research Organization (CRO), ensured quality, consistency and completeness of the data through comprehensive data management and monitoring.

Sigmund Silber, M.D., F.A.C.C., F.E.S.C., a professor of medicine with the Cardiology Practice and Hospital, Munich, and co-principle investigator, said, "Physicians rely on evidence-based recommendations for coronary interventions, and results from multicenter studies are more meaningful than those from a single center. The results from the large, multicenter e-HEALING study demonstrate the safety and efficacy of the Genous Bio-engineered R stent in a broad patient population - including remarkable outcomes for diabetic patients. This patient population shows a similar clinical outcome at 12-month follow-up compared to the total e-HEALING cohort, which demonstrates great potential for the stent in treating diabetic patients."

About Genous

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

OrbusNeich's Genous Bio-engineered R stent has been commercially available in over 60 countries since 2005. The Genous stent has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 5,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Bio-engineered R stent, as well as stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent, Scoreflex(TM), SafeCut(TM), Sapphire(TM), Sapphire NC, Avita(TM), Avita HP and Lumina(TM). OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo, Japan; and Shenzhen, China. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit

SOURCE OrbusNeich
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cadient Group Selected as Finalist in Medical Marketing & Media Awards
2. Prix Galien USA Announces 2009 Final Candidates
3. Quest Diagnostics Announces Final Tender Offer Results
4. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
5. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
6. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
7. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
8. Quest Diagnostics Finalizes Previously Announced Settlement With Government Related to Test Kit Subsidiary Closed in 2006
9. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
10. University of Maryland Announces Finalists for $75K Business Plan Competition
11. Impact Systems' Compliance-in-a-Box™ Video is Announced as "Be the Buzz of Bio" Contest Finalist
Post Your Comments:
(Date:11/25/2015)... --> ... 2020 report analyzes that automating biobanking workflow will ... long-term samples, minimizing manual errors, improving the workflow ... errors such as mislabeling or inaccurate sample barcoding ... a vital role in blood fractionation, DNA extraction, ...
(Date:11/25/2015)... ANGELES and HOLLISTON, Mass. ... Technology, Inc. (Nasdaq: HART ), a biotechnology company ... that CEO Jim McGorry will present at ... December 1, 2015 at 2:30 p.m. PT. The presentation ... below) for 30 days. Management will also be available ...
(Date:11/25/2015)... 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... a fireside chat discussion at the Piper Jaffray 27th ... . The discussion is scheduled for Wednesday, December 2, ... .  A replay will be available for 14 days ... , Julie NormartVP, Corporate Communications and Business Development , ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association (USGA) today ... Green Section Award. Presented annually since 1961, the USGA Green Section Award recognizes an ... turfgrass. , Clarke, of Iselin, N.J., is an extension specialist of turfgrass ...
Breaking Biology Technology:
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
(Date:10/29/2015)... 2015 Daon, a global leader in mobile ... a new version of its IdentityX Platform , ... America have already installed IdentityX v4.0 and ... FIDO UAF certified server component as an ... FIDO features. These customers include some of the largest ...
Breaking Biology News(10 mins):